Publications by authors named "Elizabeth Dito"

Claim this Profile
A
A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma.
Andrew H Ko, Tanios Bekaii-Saab, Jessica Van Ziffle, Olga M Mirzoeva, Nancy M Joseph, Elizabeth Dito

Clin Cancer Res· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer.
Andrew H Ko, Thach-Giao Truong, Emily Kantoff, Kimberly A Jones, Elizabeth Dito

Cancer Chemother Pharmacol· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas.
Andrew H Ko, Anne M Espinoza, Kimberly A Jones, Alan P Venook, Emily K Bergsland, Elizabeth Dito

Am J Clin Oncol· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer.
Andrew H Ko, Alan P Venook, Emily K Bergsland, R Kate Kelley, W Michael Korn, Elizabeth Dito

Cancer Chemother Pharmacol· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?
Andrew H Ko, Elizabeth Dito, Brian Schillinger, Alan P Venook, Zhidong Xu

Invest New Drugs· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study.
Andrew H Ko, Elizabeth Dito, Brian Schillinger, Alan P Venook, Emily K Bergsland

Cancer Invest· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer.
Andrew H Ko, Jeanne M Quivey, Alan P Venook, Emily K Bergsland, Elizabeth Dito

Int J Radiat Oncol Biol Phys· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas.
Andrew H Ko, Elizabeth Dito, Brian Schillinger, Alan P Venook, Emily K Bergsland

J Clin Oncol· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis